74 studies found for:    "PCI-32765"
Show Display Options
Rank Status Study
1 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
2 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
3 Recruiting Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
4 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
5 Recruiting Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide, Ibrutinib, Rituximab
6 Completed A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: PCI-32765 (Treatment A);   Drug: PCI-32765 (Treatment B);   Drug: PCI-32765 (Treatment C);   Drug: 13C6 PCI-32765 (reference)
7 Not yet recruiting A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
8 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
9 Active, not recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
10 Active, not recruiting A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
11 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
12 Completed A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Condition: Healthy Volunteers
Interventions: Drug: Sequence 1: PCI-32765;   Drug: Sequence 2: PCI-32765;   Drug: Sequence 3: PCI-32765;   Drug: Sequence 4: PCI-32765;   Drug: Sequence 5: PCI-32765
13 Not yet recruiting A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Moxifloxacin;   Drug: Ibrutinib-matching placebo;   Drug: Moxifloxacin-matching placebo
14 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
15 Recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Conditions: Progressive Hairy Cell Leukemia, Initial Treatment;   Refractory Hairy Cell Leukemia;   Untreated Hairy Cell Leukemia
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
17 Active, not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
18 Recruiting Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
19 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: ibrutinib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years